XBIO · trading date Oct 12, 2026 · previous close $2.18 · source: Alpaca (IEX feed, not consolidated full-market data).
Key Financials
Revenue
$2.98M
Net income
-$2.68M
Total assets
$8.36M
Total liabilities
$968.0K
Stockholders' equity
$7.40M
Cash & equivalents
$7.88M
Operating income
-$2.83M
Operating cash flow
-$2.29M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-03-12.
A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-95.2%
Net margin
-90.1%
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
11.6%
Equity / assets
88.4%
CapEx / revenue
—
Operating cash flow / net income
0.85×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Framingham, MA 01701
945 CONCORD ST.
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:34 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.